A safer ride: the latest innovation in targeted cancer treatment
November 28, 2019 / ABI MILLAR
One downside of the antibody-drug conjugates used in oncology today is that the drug-carrying antibodies can shed much of their toxic cargo on the way to the tumour site. Now, German researchers have published their method for attaching drugs to antibodies with greater stability, potentially making this treatment much safer. We find out more.